Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | CTSS | P25774 | 8/20 | 0.63 |
| ▸ | CTSK | P43235 | 7/20 | 0.63 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | CTSL | P07711 | 2/20 | 0.63 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.51 |
| ▸ | ITGAV | P06756 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.51 |
| ▸ | PTPRB | P23467 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3944495 | 0.92 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL9610766 | 0.92 | HDAC8 (0.72) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667405 | 0.89 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3667404 | 0.89 | HDAC8 (0.64) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL10710309 | 0.89 | HDAC8 (0.61) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3006410 | 0.88 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007610 | 0.88 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL31075430 | 0.88 | CTSS (0.65) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3007613 | 0.88 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL | |
| SCHEMBL3006406 | 0.88 | HDAC8 (0.63) | HDAC8CTSSCTSKCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | HDAC8 3469/4885CTSS 2015/4885CTSK 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.